<p>Virtus Investment Advisers LLC 在最近向证券交易委员会提交的文件中表示，在第二季度减少了对 Cogent Biosciences, Inc. (NASDAQ:COGT - 免费报告) 的持股比例，降幅为 33.8%。该公司在此期间出售了 6,663 股后，持有该科技公司 13,024 股股票。Virtus Investment Advisers LLC 在 Cogent Biosciences 的持股在最近的报告期末价值为 94,000 美元。</p>
<p>其他一些对冲基金最近也买卖了该公司的股票。Strs Ohio 在第一季度购买了 Cogent Biosciences 的新头寸，价值约为 36,000 美元。CWM LLC 在第一季度将其在 Cogent Biosciences 的持股比例提高了 11,869.9%。CWM LLC 现在拥有 8,738 股该科技公司的股票，价值 52,000 美元，此前在此期间又购买了 8,665 股。Ameritas Investment Partners Inc. 在第二季度将其在 Cogent Biosciences 的持股比例增长了 16.6%。Ameritas Investment Partners Inc. 现在拥有 10,839 股该科技公司的股票，价值 78,000 美元，此前在上个季度又购买了 1,543 股。Prudential Financial Inc. 在第二季度购买了 Cogent Biosciences 的新头寸，价值约为 93,000 美元。最后，49 Wealth Management LLC 在第二季度将其在 Cogent Biosciences 的持股比例提高了 19.0%。49 Wealth Management LLC 现在拥有 15,508 股该科技公司的股票，价值 111,000 美元，此前在此期间又购买了 2,476 股。</p>
<p>获取 <strong>Cogent Biosciences</strong> 警报：</p>
<h2>华尔街分析师观点</h2>
<p>几家券商最近对 COGT 发表了评论。Weiss Ratings 在 11 月 24 日的研究报告中重申了对 Cogent Biosciences 股票的 &#34;卖出 (d-)&#34; 评级。摩根大通将 Cogent Biosciences 的目标价格从 30.00 美元上调至 44.00 美元，并在 10 月 21 日的研究报告中给予该股票 &#34;超配&#34; 评级。Leerink Partners 在 11 月 10 日的报告中将 Cogent Biosciences 的目标价格从 18.00 美元上调至 50.00 美元，并给予公司 &#34;跑赢大盘&#34; 评级。Stifel Nicolaus 在 11 月 10 日的报告中将 Cogent Biosciences 的评级从 &#34;持有&#34; 上调至 &#34;买入&#34;，并为该公司设定了 40.00 美元的目标价格。最后，Guggenheim 在 8 月 25 日的研究报告中将 Cogent Biosciences 的目标价格从 17.00 美元上调至 20.00 美元，并给予公司 &#34;买入&#34; 评级。两位投资分析师对该股票给予了强烈买入评级，九位给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Cogent Biosciences 的平均评级为 &#34;适度买入&#34;，平均目标价格为 32.33 美元。</p>
<p><strong>查看我们最新的 COGT 股票报告</strong></p>
<h2>Cogent Biosciences 股票下跌 0.6%</h2>
<p>Cogent Biosciences 股票周一开盘价为 40.16 美元。该公司的市值为 57.2 亿美元，市盈率为 -24.48，贝塔值为 0.49。该股票的 50 日简单移动平均线为 21.44 美元，200 日简单移动平均线为 13.81 美元。Cogent Biosciences, Inc. 的 52 周低点为 3.72 美元，52 周高点为 41.27 美元。该公司的债务与股本比率为 0.23，流动比率为 6.38，速动比率为 6.38。</p>
<p>Cogent Biosciences (NASDAQ:COGT - 获取免费报告) 最近在 11 月 3 日发布了季度财报。该科技公司报告每股收益为 ($0.50)，超出市场共识预期的 ($0.54) 0.04 美元。平均而言，股票研究分析师预计 Cogent Biosciences, Inc. 本财年的每股收益将为 -2.42。</p>
<h2>关于 Cogent Biosciences</h2>
<p>(免费报告)</p>
<p>Cogent Biosciences, Inc. 是一家生物技术公司，专注于开发针对基因定义疾病的精准疗法。其主要产品候选药物包括 bezuclastinib (CGT9486)，这是一种选择性酪氨酸激酶抑制剂，旨在针对 KIT 受体酪氨酸激酶中的突变，包括驱动全身性肥大细胞增多症的 KIT D816V 突变，以及在晚期胃肠道间质瘤患者中发现的 KIT 外显子 17 的其他突变。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票，而不是 Cogent Biosciences</li>
<li>股息支付比率计算器</li>
<li>Bath &amp; Body Works 创下多年低点：是机会还是陷阱？</li>
<li>成长投资：您应该在 2022 年采用这种投资策略吗？</li>
<li>担心通货膨胀？这三只 ETF 提供真正的保护</li>
<li>如何在 5 个简单步骤中做空股票</li>
<li>英特尔的黑色星期五突破：苹果传闻推动假日反弹</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q09HVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q09HVA"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元在 Cogent Biosciences 吗？</h2>
<p>在您考虑投资 Cogent Biosciences 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买... 而 Cogent Biosciences 并不在名单上。</p>
<p>虽然 Cogent Biosciences 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

COGT

<p>Virtus Investment Advisers LLC 在第二季度减少了对 Cogent Biosciences 的持股比例，降幅为 33.8%，目前持有 13,024 股，价值 94,000 美元。分析师对 Cogent 的评级褒贬不一，普遍共识为 “适度买入”，目标价为 32.33 美元。该股票开盘价为 40.16 美元，市值为 57.2 亿美元。Cogent 专注于针对基因定义疾病的精准治疗</p>

<p>Virtus Investment Advisers LLC lessened its stake in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 33.8% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 13,024 shares of the technology company's stock after selling 6,663 shares during the period. Virtus Investment Advisers LLC's holdings in Cogent Biosciences were worth $94,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Virtus Investment Advisers LLC 在最近向证券交易委员会提交的文件中表示，在第二季度减少了对 Cogent Biosciences, Inc. (NASDAQ:COGT - 免费报告) 的持股比例，降幅为 33.8%。该公司在此期间出售了 6,663 股后，持有该科技公司 13,024 股股票。Virtus Investment Advisers LLC 在 Cogent Biosciences 的持股在最近的报告期末价值为 94,000 美元。</p>
</div><p>A number of other hedge funds also recently bought and sold shares of the company. Strs Ohio purchased a new position in shares of Cogent Biosciences in the first quarter worth approximately $36,000. CWM LLC boosted its stake in Cogent Biosciences by 11,869.9% in the 1st quarter. CWM LLC now owns 8,738 shares of the technology company's stock worth $52,000 after purchasing an additional 8,665 shares during the period. Ameritas Investment Partners Inc. grew its position in Cogent Biosciences by 16.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 10,839 shares of the technology company's stock worth $78,000 after purchasing an additional 1,543 shares in the last quarter. Prudential Financial Inc. purchased a new position in Cogent Biosciences during the 2nd quarter worth approximately $93,000. Finally, 49 Wealth Management LLC raised its stake in Cogent Biosciences by 19.0% during the 2nd quarter. 49 Wealth Management LLC now owns 15,508 shares of the technology company's stock valued at $111,000 after purchasing an additional 2,476 shares during the period.</p>
<div class="lb-trans"><p>其他一些对冲基金最近也买卖了该公司的股票。Strs Ohio 在第一季度购买了 Cogent Biosciences 的新头寸，价值约为 36,000 美元。CWM LLC 在第一季度将其在 Cogent Biosciences 的持股比例提高了 11,869.9%。CWM LLC 现在拥有 8,738 股该科技公司的股票，价值 52,000 美元，此前在此期间又购买了 8,665 股。Ameritas Investment Partners Inc. 在第二季度将其在 Cogent Biosciences 的持股比例增长了 16.6%。Ameritas Investment Partners Inc. 现在拥有 10,839 股该科技公司的股票，价值 78,000 美元，此前在上个季度又购买了 1,543 股。Prudential Financial Inc. 在第二季度购买了 Cogent Biosciences 的新头寸，价值约为 93,000 美元。最后，49 Wealth Management LLC 在第二季度将其在 Cogent Biosciences 的持股比例提高了 19.0%。49 Wealth Management LLC 现在拥有 15,508 股该科技公司的股票，价值 111,000 美元，此前在此期间又购买了 2,476 股。</p>
</div><p>Get <strong>Cogent Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Cogent Biosciences</strong> 警报：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Several brokerages have recently commented on COGT. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Cogent Biosciences in a research report on Monday, November 24th. JPMorgan Chase &amp; Co. raised their price objective on Cogent Biosciences from $30.00 to $44.00 and gave the stock an &#34;overweight&#34; rating in a research report on Tuesday, October 21st. Leerink Partners upped their target price on Cogent Biosciences from $18.00 to $50.00 and gave the company an &#34;outperform&#34; rating in a report on Monday, November 10th. Stifel Nicolaus upgraded shares of Cogent Biosciences from a &#34;hold&#34; rating to a &#34;buy&#34; rating and set a $40.00 price target for the company in a report on Monday, November 10th. Finally, Guggenheim upped their price objective on shares of Cogent Biosciences from $17.00 to $20.00 and gave the company a &#34;buy&#34; rating in a research note on Monday, August 25th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Cogent Biosciences has an average rating of &#34;Moderate Buy&#34; and an average target price of $32.33.</p>
<div class="lb-trans"><p>几家券商最近对 COGT 发表了评论。Weiss Ratings 在 11 月 24 日的研究报告中重申了对 Cogent Biosciences 股票的 &#34;卖出 (d-)&#34; 评级。摩根大通将 Cogent Biosciences 的目标价格从 30.00 美元上调至 44.00 美元，并在 10 月 21 日的研究报告中给予该股票 &#34;超配&#34; 评级。Leerink Partners 在 11 月 10 日的报告中将 Cogent Biosciences 的目标价格从 18.00 美元上调至 50.00 美元，并给予公司 &#34;跑赢大盘&#34; 评级。Stifel Nicolaus 在 11 月 10 日的报告中将 Cogent Biosciences 的评级从 &#34;持有&#34; 上调至 &#34;买入&#34;，并为该公司设定了 40.00 美元的目标价格。最后，Guggenheim 在 8 月 25 日的研究报告中将 Cogent Biosciences 的目标价格从 17.00 美元上调至 20.00 美元，并给予公司 &#34;买入&#34; 评级。两位投资分析师对该股票给予了强烈买入评级，九位给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Cogent Biosciences 的平均评级为 &#34;适度买入&#34;，平均目标价格为 32.33 美元。</p>
</div><p><strong>View Our Latest Stock Report on COGT</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 COGT 股票报告</strong></p>
</div><h2>Cogent Biosciences Stock Down 0.6%</h2>
<div class="lb-trans"><h2>Cogent Biosciences 股票下跌 0.6%</h2>
</div><p>Shares of Cogent Biosciences stock opened at $40.16 on Monday. The firm has a market cap of $5.72 billion, a price-to-earnings ratio of -24.48 and a beta of 0.49. The stock has a 50-day simple moving average of $21.44 and a 200-day simple moving average of $13.81. Cogent Biosciences, Inc. has a 52-week low of $3.72 and a 52-week high of $41.27. The company has a debt-to-equity ratio of 0.23, a current ratio of 6.38 and a quick ratio of 6.38.</p>
<div class="lb-trans"><p>Cogent Biosciences 股票周一开盘价为 40.16 美元。该公司的市值为 57.2 亿美元，市盈率为 -24.48，贝塔值为 0.49。该股票的 50 日简单移动平均线为 21.44 美元，200 日简单移动平均线为 13.81 美元。Cogent Biosciences, Inc. 的 52 周低点为 3.72 美元，52 周高点为 41.27 美元。该公司的债务与股本比率为 0.23，流动比率为 6.38，速动比率为 6.38。</p>
</div><p>Cogent Biosciences (NASDAQ:COGT - Get Free Report) last issued its quarterly earnings data on Monday, November 3rd. The technology company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.04. On average, equities research analysts expect that Cogent Biosciences, Inc. will post -2.42 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Cogent Biosciences (NASDAQ:COGT - 获取免费报告) 最近在 11 月 3 日发布了季度财报。该科技公司报告每股收益为 ($0.50)，超出市场共识预期的 ($0.54) 0.04 美元。平均而言，股票研究分析师预计 Cogent Biosciences, Inc. 本财年的每股收益将为 -2.42。</p>
</div><h2>About Cogent Biosciences</h2>
<div class="lb-trans"><h2>关于 Cogent Biosciences</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.</p>
<div class="lb-trans"><p>Cogent Biosciences, Inc. 是一家生物技术公司，专注于开发针对基因定义疾病的精准疗法。其主要产品候选药物包括 bezuclastinib (CGT9486)，这是一种选择性酪氨酸激酶抑制剂，旨在针对 KIT 受体酪氨酸激酶中的突变，包括驱动全身性肥大细胞增多症的 KIT D816V 突变，以及在晚期胃肠道间质瘤患者中发现的 KIT 外显子 17 的其他突变。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Cogent Biosciences</li>
<li>Dividend Payout Ratio Calculator</li>
<li>Bath &amp; Body Works Hits Multi-Year Lows: Bargain or Trap?</li>
<li>Growth Investing: Should You Adopt This Investing Strategy in 2022?</li>
<li>Worried About Inflation? These 3 ETFs Offer Real Protection</li>
<li>How to Short a Stock in 5 Easy Steps</li>
<li>Intel’s Black Friday Breakout: Apple Rumors Fuel a Holiday Rally</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Cogent Biosciences</li>
<li>股息支付比率计算器</li>
<li>Bath &amp; Body Works 创下多年低点：是机会还是陷阱？</li>
<li>成长投资：您应该在 2022 年采用这种投资策略吗？</li>
<li>担心通货膨胀？这三只 ETF 提供真正的保护</li>
<li>如何在 5 个简单步骤中做空股票</li>
<li>英特尔的黑色星期五突破：苹果传闻推动假日反弹</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q09HVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=COGT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Cogent Biosciences Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元在 Cogent Biosciences 吗？</h2>
</div><p>Before you consider Cogent Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑投资 Cogent Biosciences 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cogent Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买... 而 Cogent Biosciences 并不在名单上。</p>
</div><p>While Cogent Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Cogent Biosciences 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Virtus Investment Advisers LLC 在 Cogent Biosciences, Inc. $COGT 持有价值 94,000 美元的股票头寸